PMID- 16951391
OWN - NLM
STAT- MEDLINE
DCOM- 20061026
LR  - 20151119
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 11
IP  - 8
DP  - 2006 Sep
TI  - Chromogenic in situ hybridization to detect HER-2/neu gene amplification in 
      histological and ThinPrep-processed breast cancer fine-needle aspirates: a 
      sensitive and practical method in the trastuzumab era.
PG  - 878-86
AB  - The increasing evidence of trastuzumab efficacy in breast cancer (BC) patients 
      means that an accurate and reproducible evaluation of HER-2 statusis of paramount 
      importance in histological and in cytological samples. Currently, the two main 
      methods used to analyze HER-2 amplification or overexpression are fluorescence in 
      situ hybridization (FISH) and immunohistochemistry (IHC). Although the two 
      methods are strongly correlated for histological tissue, the evaluation of tumor 
      morphology through FISH may be difficult and fluorescence fades quickly. These 
      limitations can be overcome by chromogenic in situ hybridization (CISH), which 
      can visualize the amplification product along with morphological features. In 
      view of this, in the present study, we analyzed the usefulness of CISH on 
      formalin-fixed, paraffin-embedded (FFPE) BC specimens and investigated whether 
      CISH can be a valid technique in the determination of HER-2 status for 
      fine-needle aspirates (FNAs) processed by liquid-based cytology. The results we 
      obtained in a retrospective series of 111 FFPE BC specimens demonstrated good 
      concordance between CISH and IHC and between CISH and FISH. The former 
      concordance was comparable with that observed between FISH and IHC. When CISH was 
      applied to a prospective series of 53 FNAs, from surgically removed BC, our data 
      showed evidence of a higher concordance of results between liquid-based cytology 
      and the companion FFPE tissues using CISH rather than HercepTesttrade mark. 
      Therefore, CISH analysis, which is avaluable and reproducible alternative to FISH 
      for selecting breast cancer patients for trastuzumab therapy, can lower 
      false-positive immunocytochemistry findings in ThinPrep-processed FNAs.
FAU - Vocaturo, Amina
AU  - Vocaturo A
AD  - Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy. 
      vocaturo@ifo.it
FAU - Novelli, Flavia
AU  - Novelli F
FAU - Benevolo, Maria
AU  - Benevolo M
FAU - Piperno, Giulia
AU  - Piperno G
FAU - Marandino, Ferdinando
AU  - Marandino F
FAU - Cianciulli, Anna Maria
AU  - Cianciulli AM
FAU - Merola, Roberta
AU  - Merola R
FAU - Donnorso, Raffaele Perrone
AU  - Donnorso RP
FAU - Sperduti, Isabella
AU  - Sperduti I
FAU - Buglioni, Simonetta
AU  - Buglioni S
FAU - Mottolese, Marcella
AU  - Mottolese M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Chromogenic Compounds)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Biopsy, Fine-Needle
MH  - Breast Neoplasms/*drug therapy/*genetics
MH  - *Chromogenic Compounds
MH  - Female
MH  - Gene Amplification
MH  - Histocytological Preparation Techniques
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - *In Situ Hybridization
MH  - In Situ Hybridization, Fluorescence
MH  - Paraffin Embedding
MH  - Prospective Studies
MH  - Receptor, ErbB-2/*genetics
MH  - Retrospective Studies
MH  - Sensitivity and Specificity
MH  - Trastuzumab
EDAT- 2006/09/05 09:00
MHDA- 2006/10/27 09:00
CRDT- 2006/09/05 09:00
PHST- 2006/09/05 09:00 [pubmed]
PHST- 2006/10/27 09:00 [medline]
PHST- 2006/09/05 09:00 [entrez]
AID - 11/8/878 [pii]
AID - 10.1634/theoncologist.11-8-878 [doi]
PST - ppublish
SO  - Oncologist. 2006 Sep;11(8):878-86. doi: 10.1634/theoncologist.11-8-878.